Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Saiga AI, Iwai K, Hayakawa T, Takahata Y, Kitamura S, Nishimura T, et al
Clean label, vegan, 3rd party tested
Strengths of our study are its relatively large sample size and the virtually complete follow-up of the ALS patient cohort 17
The phase 3 TRIUMPH-4 data showed these rates at 9 mg and 12 mg doses respectively: Nausea: 38.1% and 43.2% (vs 10.7% placebo) Diarrhea: 34.7% and 33.1% (vs 13.4% placebo) Constipation: 21.8% and 25.0% (vs 8.7% placebo) Vomiting: 20.4% and 20.9% (vs placebo) These numbers are higher than cagrilintide monotherapy across the board
US$ 21.89
US$ 28.31
US$ 26.59
US$ 28.66
US$ 28.53
US$ 25.08
